Published in Drug Law Weekly, January 4th, 2005
The new synthesis process provides for a novel approach affording lower costs due to fewer steps and increased yields.
The patent was granted to WellSpring Pharmaceutical Corporation, holder of worldwide rights to the product, who in turn has licensed commercial rights to InfaCare. The patent provides a period of coverage of 20 years.
Stanate is an investigational drug in late stage...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.